Connect with us

Stocks to Watch

Have You Connected The Dots With This Stock Price Exclusive

Joe Samuel

Published

on

We’ve been monitoring the progress of Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) for several weeks now and it managed to hit fresh highs of $0.80 on strong, opening bell momentum on December 12. Keep in mind that within just the last 4 days, we’ve seen this jump from lows of $0.57 to December 12 highs of $0.80; a move of 40%. We mention this because Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) pulled back but what has happened since then is what we’re looking at right now.

Instead of falling apart, Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) held a level that was once its previous high that we saw early this quarter. Furthermore, it didn’t just hold this level, it has since bounced back BIG from that level. By the closing bell, Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) ran back to close out the day at $0.75 to make a rebound of 15% from its lows.

PHGRF chart 12 12

Keep in mind that EVERY DAY this week, the afternoon session has been VERY active, which is why we said above that we’re looking to the December 13th session to see what happens next.

For three consecutive days, the momentum we saw during the second half of the day has been nothing short of impressive. In fact on December 12th, Premier pulled back from $0.76 to $0.71.  But once again, during the last hour of the day, Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) saw bullish action and a push back to $0.75 by the closing bell:

This was the same trend we saw for two days prior and everyone watching watched how a strong close ended up continuing into a strong open the next day. Can we see this on “day four”?

Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) & Its Opportunity Within Canada’s Medical Marketplace

This latest move has been on the heels of Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI)‘s latest announcement where they have just signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy. As far as timing is concerned, the expected closing isn’t years away; the Company expects the acquisition to close in or about Q1-19.

For the fiscal year 2017/18, the pharmacy has revenues of approximately $1MM and Adjusted EBITDA of about 30%.

“We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-based patient-centric model,” said Dr. Essam Hamza, CEO of Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI)

The pharmacy industry in Canada could be on the cusp of big potential now that cannabis is legal.  In fact, pharmacies like Shoppers Drug Mart, for example, have been granted a license to sell medical marijuana online and we’re sure they won’t be the only ones.

Health Canada’s list of authorized cannabis sellers and producers has been updated to reflect that the pharmacy can sell dried and fresh cannabis, as well as plants, seeds, and oil.

The spectrum of offerings has just been widened and those companies getting a foot in the Canadian pharmacy market right now could have the upper hand as this market continues to expand.

Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) not only has a large patient pool and a “foot in the door” with this LOI, but they’ve also got telehealth technology in place to stay at the forefront of this new market directive! Just look at what the MAJOR cannabis companies are starting to do.

Aurora Cannabis, for example, just purchased Farmacias Magistrales in Mexico…they’re going after pharmacies to grow! Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) is already hot on this trail while also having MORE PATIENTS under its umbrella than some of the largest cannabis companies in the industry.

When we talk about timing and connecting the dots, this is what we’re talking about. With Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) managing to hit new highs during the last three sessions, could the second half of the week have more momentum in store?

Click Here To Read The Full Report On Premier Health Group (OTC: PHGRF) (CSE: PHGI)

stock market today

DISCLAIMER:  Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full disclaimer..

Continue Reading
Click to comment

Biotechnology

3 Penny Stocks Looking To Change The Biotech Industry

Jon Phillip

Published

on

biotechnology stocks

The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.

Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, INVESTORS & THE WORLD

GT Biopharma Inc. (GTBP)

One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.

biotechnology stocks to buy now

So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.

TriKE Therapy

One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.

“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.”  Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.

Conatus Pharmaceuticals Inc. (CNAT)

This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.

biotechnology stocks to watch

In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.

Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.

Nuvectra Corporation (NVTR)

To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.

breakthrough biotech stocks to watch

Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.

Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, INVESTORS & THE WORLD

biotechnology stocks

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here

Continue Reading

Biotechnology

Are These Biotech Names On Your October Watch List?

Joe Samuel

Published

on

biotech stock price

Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.

Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.

Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)

If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

best biotechnology stocks to buy now

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.

Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)                                           

The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.

The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.

Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.

Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)

The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.

The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.

list of healthcare stocks to watch

Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.

Continue Reading

Biotechnology

Are These 3 Biotech Stocks On Your Watch List in October?

A. Lawrence

Published

on

Small-Cap Biotechnology Stocks Are Starting To Outperform Blue-Chips

Biotechnology stocks are currently performing well hitting new milestones in terms of share performance. Despite growing concerns of increased regulation on domestic pricing established biotechnology companies with establishing market position will continue to thrive.

Small-cap stocks can be outstanding growth vehicles for the risk-averse crowd. On balance, stocks with market caps below $2 billion have trounced the broader markets over the past two decades. The downside is that small-cap stocks tend to be on the volatile side.

But if you can handle volatility, it may be time to turn your attention to this area of the market. Here are three biotech stocks to watch that have promising potential in the near term.

GT Biopharma (GTBP)

Whenever you think of biotechnology or biopharma stocks, what comes to mind? For most, it’s the fact that the smaller companies tend to go after major breakthrough therapies. The general hopes are that the company could get bought out by a larger company or score a key win from the FDA. But what needs to be in place is the right framework and a general proof of concept.

biotechnology stocks to buy now 2019

Needless to say, small-cap companies strive to achieve this. New findings may suggest GT Biopharma (GTBP) therapies could eliminate HIV infected cells. You read that right. The company’s therapy showed that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could actually be eliminated (Click For More Details On This).

The Problem: Despite the use of anti-retroviral drugs, infected individuals retain reservoirs of latent HIV-infected cells that, upon cessation of antiretroviral drug therapy, can reactivate and re-establish an active HIV infection. For curative therapy, the destruction of these latent HIV infected cells must take place.

At the University of Minnesota GT Biopharma (GTBP) presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg and discussed its design of an HIV-TriKE™ containing an antigen-binding fragment from a broadly-neutralizing antibody targeting the HIV-Env protein. The HIV-TriKE™ is designed to target HIV while redirecting NK cell killing specifically to actively replicating HIV infected cells.

The TriKE™ technology is able to be extended to the treatment of infectious disease, and is able to kill HIV in the reservoir.”

Anthony Cataldo , the Chairman and Chief Executive Officer of GT Biopharma

BioDelivery Sciences International (BDSI)

BioDelivery Sciences International Inc. (NASDAQ:BDSI) has been gaining momentum so far in October, with a jump of 12%. The company in its most recent quarter beat analysts’ estimates of $25.30 million in revenue and posted revenue of around $29.68.

The company recently announced that from October 1st, a PBM will commence provision of enhanced access of patients to BELBUCA CII and Symproic tablets. With this, around 14 million patients to gain access to BELBUCA as a buprenorphine product in their coverage plans and Symproic as the preferable exclusive product.

biotech stock to buy 2019

BELBUCA has approval in the US for treatment of severe pain that requires constant long-term opioid treatment for which other treatment alternatives are inadequate. This Schedule III drug presents much potential for the company considering it is not prone to abuse.

Agile Therapeutics (AGRX)

Agile Therapeutics Inc. (NASDAQ:AGRX) is also another biotechnology stock to watch that has some promising developments. Recently the company indicated that it was in the final stages of a clinical study for its lead product Twirla.

The company has committed all its resources in the development of the product. Agile resubmitted Twirla for New Drug Application this year with the advisory committee expected to meet at the end of this month and then followed by PDUFA next month.

Twirla is a birth control contraceptive patch that once it receives approval will make it easier to take relative to the daily contraceptive pill. Twirla is using two active ingredients popular in contraceptives. The drug faces competition from Ortho Evra and Xulane but it will still manage to cut a share of the market from the established products. If the drug receives approval then it will be a huge development for investors. Twirla presents massive potential which is why Agile is among the Biotech stocks to watch.

top biotechnology stocks to watch today

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).  Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com